BACKGROUND: A public health concern regarding HIV pre-exposure prophylaxis (PrEP) is sexual risk compensation (ie, increased unsafe sex among PrEP users that may undermine prevention efforts). METHODS: This demonstration study (NCT#01761643; initiated in 2013) included 398 men who have sex with men who initiated PrEP and were followed over 48 weeks at 4 sites in Southern California. Wilcoxon signed-rank tests compared previous 30-day number of sex partners and condomless insertive anal sex and receptive anal sex (CIAS and CRAS, respectively) acts at weeks 4, 12, 24, 36, and 48 to baseline. At 2 sites, PrEP users were also compared with a lagged, comparison group of 99 men who have sex with men who did not receive PrEP over 24 weeks using linear regression models, adjusting for age, race/ethnicity, education, and respective baseline scores. Logistic regression compared week 24 sexually transmitted infection (STI) rates. RESULTS: Over 48 weeks in the PrEP group, there were significant decreases in the number of unknown HIV status sex partners and increases in CRAS at all study visits; there was no consistent change in number of HIV+ sex partners or CIAS. Among participants at 2 sites, there were no significant differences between PrEP and non-PrEP users in change in number of partners, CIAS, CRAS, or STI rates at week 24. CONCLUSIONS: Among early adopters of PrEP, there is some evidence for sexual risk compensation. Results support current guidelines of regular STI screening and behavioral risk reduction and adherence counseling with the provision of PrEP.
BACKGROUND: A public health concern regarding HIV pre-exposure prophylaxis (PrEP) is sexual risk compensation (ie, increased unsafe sex among PrEP users that may undermine prevention efforts). METHODS: This demonstration study (NCT#01761643; initiated in 2013) included 398 men who have sex with men who initiated PrEP and were followed over 48 weeks at 4 sites in Southern California. Wilcoxon signed-rank tests compared previous 30-day number of sex partners and condomless insertive anal sex and receptive anal sex (CIAS and CRAS, respectively) acts at weeks 4, 12, 24, 36, and 48 to baseline. At 2 sites, PrEP users were also compared with a lagged, comparison group of 99 men who have sex with men who did not receive PrEP over 24 weeks using linear regression models, adjusting for age, race/ethnicity, education, and respective baseline scores. Logistic regression compared week 24 sexually transmitted infection (STI) rates. RESULTS: Over 48 weeks in the PrEP group, there were significant decreases in the number of unknown HIV status sex partners and increases in CRAS at all study visits; there was no consistent change in number of HIV+ sex partners or CIAS. Among participants at 2 sites, there were no significant differences between PrEP and non-PrEP users in change in number of partners, CIAS, CRAS, or STI rates at week 24. CONCLUSIONS: Among early adopters of PrEP, there is some evidence for sexual risk compensation. Results support current guidelines of regular STI screening and behavioral risk reduction and adherence counseling with the provision of PrEP.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Luxi Lal; Jennifer Audsley; Dean A Murphy; Christopher K Fairley; Mark Stoove; Norm Roth; Richard Moore; Ban K Tee; Nalagafiar Puratmaja; Peter L Anderson; David Leslie; Robert M Grant; John De Wit; Edwina Wright Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Nina S Kadan-Lottick; Leslie L Robison; James G Gurney; Joseph P Neglia; Yutaka Yasui; Robert Hayashi; Melissa Hudson; Mark Greenberg; Ann C Mertens Journal: JAMA Date: 2002-04-10 Impact factor: 157.335
Authors: Samuel M Jenness; Akshay Sharma; Steven M Goodreau; Eli S Rosenberg; Kevin M Weiss; Karen W Hoover; Dawn K Smith; Patrick Sullivan Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Virginia A Fonner; Sarah L Dalglish; Caitlin E Kennedy; Rachel Baggaley; Kevin R O'Reilly; Florence M Koechlin; Michelle Rodolph; Ioannis Hodges-Mameletzis; Robert M Grant Journal: AIDS Date: 2016-07-31 Impact factor: 4.177
Authors: Lisa B Hightow-Weidman; Manya Magnus; Geetha Beauchamp; Christopher B Hurt; Steve Shoptaw; Lynda Emel; Estelle Piwowar-Manning; Kenneth H Mayer; LaRon E Nelson; Leo Wilton; Phaedrea Watkins; Darren Whitfield; Sheldon D Fields; Darrell Wheeler Journal: Clin Infect Dis Date: 2019-10-15 Impact factor: 9.079
Authors: Martin Hoenigl; Erin Morgan; Donald Franklin; Peter L Anderson; Elizabeth Pasipanodya; Matthew Dawson; Marvin Hanashiro; Eric E Ellorin; Jill Blumenthal; Robert Heaton; David J Moore; Sheldon R Morris Journal: J Neurovirol Date: 2019-01-07 Impact factor: 2.643
Authors: Nathan W Furukawa; Jessica L Maksut; Maria Zlotorzynska; Travis H Sanchez; Dawn K Smith; Stefan D Baral Journal: Am J Prev Med Date: 2020-05-04 Impact factor: 5.043
Authors: Elizabeth C Pasipanodya; Michael J Li; Sonia Jain; Xiaoying Sun; Jessica Tobin; Eric Ellorin; Michael Dube; Eric S Daar; Katya Corado; Joel Milam; Jill Blumenthal; Sheldon H Morris; David J Moore Journal: AIDS Behav Date: 2020-11